Charles River Laboratories International, Inc.
Equities
CRL
US1598641074
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
201.5 USD | -0.87% |
|
-2.38% | -14.77% |
06-28 | Argus Downgrades Charles River Laboratories International to Hold From Buy | MT |
06-25 | Charles River Laboratories, Gates Institute Collaborate on Lentiviral Vector Manufacturing | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.77% | 10.38B | |
+17.72% | 44.87B | |
-10.33% | 37.8B | |
+37.55% | 37.61B | |
+29.36% | 31.32B | |
-8.44% | 27.4B | |
+12.45% | 26.32B | |
+44.19% | 14.07B | |
+31.93% | 12.5B | |
-7.67% | 11.23B |
- Stock Market
- Equities
- CRL Stock
- News Charles River Laboratories International, Inc.
- Transcript : Charles River Laboratories International, Inc. Presents at 36th Annual J.P. Morgan Healthcare Conference, Jan-08-2018 through Jan-11-2018